Unknown

Dataset Information

0

New clinical findings in the fragile X-associated tremor ataxia syndrome (FXTAS).


ABSTRACT: The objective of this paper was to assess the phenotypic variance in patients with the Fragile X-associated Tremor Ataxia Syndrome (FXTAS) and to further elucidate genotype-phenotype correlations in the illness. A second goal was to generate hypotheses regarding symptom progression based on careful histories in our sample that can now be tested in ongoing longitudinal studies. The variability of clinical signs and symptom progression in FXTAS complicates our understanding of its phenotype and presents a series of problems in clinical trial design. Similarly, pre-motor and non-motor symptoms have not been adequately explored to answer outstanding questions regarding genotype-phenotype associations in FXTAS. This was a cross-sectional study of FMR1 premutation carriers from known fragile X syndrome pedigrees. We report on the first 50 subjects who have completed a full neurologic evaluation and a brain MRI. Subjects were selected on the basis of motor symptoms or abnormal results (>1 SD) on a quantitative instrument designed to detect mild tremor and ataxia (CATSYS 1994). A neuropsychological battery included the WAIS-III, COWA, and WCST. Statistical analysis used ANOVA and Fisher's exact test with p?

SUBMITTER: Juncos JL 

PROVIDER: S-EPMC3766636 | biostudies-literature | 2011 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

New clinical findings in the fragile X-associated tremor ataxia syndrome (FXTAS).

Juncos Jorge L JL   Lazarus Joash T JT   Graves-Allen Emily E   Shubeck Lisa L   Rusin Michelle M   Novak Gloria G   Hamilton Deborah D   Rohr Julia J   Sherman Stephanie L SL  

Neurogenetics 20110129 2


The objective of this paper was to assess the phenotypic variance in patients with the Fragile X-associated Tremor Ataxia Syndrome (FXTAS) and to further elucidate genotype-phenotype correlations in the illness. A second goal was to generate hypotheses regarding symptom progression based on careful histories in our sample that can now be tested in ongoing longitudinal studies. The variability of clinical signs and symptom progression in FXTAS complicates our understanding of its phenotype and pr  ...[more]

Similar Datasets

| S-EPMC3904666 | biostudies-other
| S-EPMC7018079 | biostudies-literature
| S-EPMC1181968 | biostudies-literature
| S-EPMC7338407 | biostudies-literature
| S-EPMC6336371 | biostudies-literature
| S-EPMC4200486 | biostudies-literature
| S-EPMC7604678 | biostudies-literature
| S-EPMC6353491 | biostudies-literature
| S-EPMC6030249 | biostudies-literature
| S-EPMC10929604 | biostudies-literature